OSTX Company Profile and Key Details

OS Therapies Incorporated (NYSE:OSTX) closed at $1.64 USD, gaining $0.09 (6.17%) from the previous close of $1.54. The stock is currently mid-range between its 52-week high and low $1.12 and $7.00. With a market capitalization of about $57.58 million, OS Therapies Incorporated is classified as a micro-cap and shows lower-than-market volatility (beta ~-4.04). Key stats such as the average daily volume over the past year has been around 375.36 thousand shares, in line with its 52-week average. Headquartered in Rockville, MD, OS Therapies Incorporated operates in the Healthcare sector and the Biotechnology industry. Led by CEO Paul A. Romness, the company employs approximately 4 people and listed since August 01, 2024. OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.

OS Therapies Incorporated generated EPS of -$0.82 over the past year. Five-year average earnings growth is 79.38%. Wall Street analysts project EPS growth of 43.35% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 24 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $17.00. The high target offers 1198.7% upside. The low target suggests 1003.9% downside. The mean target is $19.83. This offers 1187.66% upside. OS Therapies Incorporated earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 14, 2025, missed forecasts by 31.25%. The prior quarter beat by 26.67%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 14, 2024.

OSTX has shown weak momentum, losing -24.14% over the past week and -27.36% over the past quarter, though year-to-date performance is down -64.02%. Short-term trend indicators are bullishly aligned (SMA20 -13.12%, SMA50 -15.1%, SMA200 -15.29%). The stock’s 14-day RSI is 37.06 (weak momentum), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -78.0% below its high and over 37.5% above its low. Average 10-day trading volume of 721.51 thousand shares is significantly above the 3-month average of 364.48 thousand, indicating heightened recent market interest.

OS Therapies Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.27. This means the shares are trading above this model’s fair value.

OS Therapies Incorporated has 31.62 million shares outstanding. The public float is 20.95 million shares, elevated short interest at 1.25% of float. This equals 348.36 thousand shares. The short ratio is 0.51 days. Institutional investors hold 2.77% of the float. Insiders own 31.15%.

Our AI price prediction model suggests that OS Therapies Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.65%, with price expected at $1.53 by January 02, 2026, within a range of $1.39 to $1.67 3-Month Outlook: Projected fall of -57.79%, reaching $0.65 by March 19, 2026, with a range of $0.54 to $0.77. 1-Year Outlook: Projected gain of 161.04%, with price at $4.02 by December 18, 2026, within a range of $3.94 to $4.12.

OS Therapies Incorporated (NYSE:OSTX) shares are down -64.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows OS Therapies Incorporated trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.83, suggesting 1187.66% upside. Our AI forecast model points to short-term weakness (-0.65% over two weeks), a medium-term fall (-57.79% over three months), and a longer-term gain (161.04% over one year), with expected trading ranges indicating moderate volatility.

OS Therapies Incorporated trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.05 suggesting the stock is closer to book value. The P/FCF stands at -0.01, also below market averages.